

This part of label permanently adheres to container

This part of label folds back

DOSAGE:
One tablet per 5–10 kg (20–40 mg/kg) daily or in divided dose every 12 hours with food. Select initial dose according to the degree of sedation experienced with concurrent therapy. After 30 days adjust dosage according to serum bromide concentrations and clinical response.

MONITORING:
Maintaining therapeutic steady-state concentrations increases efficacy. Trough serum bromide and phenobarbitone concentrations should be measured at 30 and 120 days and every 6 months during therapy or if adverse effects occur. Trough serum bromide concentrations should be between 0.7–2 mg/mL. Higher concentrations may result in sedation and ataxia. Concurrent trough serum phenobarbitone concentrations should be 25–30 µg/mL. Liver function should also be monitored at these times. When bromide approaches steady-state concentrations in the therapeutic range and seizures are under control, reduction in phenobarbitone dosage can be attempted.

DIET:
Due to competition between bromide and chloride ions, the chloride intake can significantly influence serum bromide concentrations. High chloride diets will increase bromide excretion while low diets will increase serum bromide concentrations. Attention therefore needs to be given to chloride intake, especially if a change of diet occurs.

PEEL BACK

APPROVED LABEL

Infopest Verified

**PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY**

**BROMAV 200mg
TABLETS FOR DOGS**

Active constituent: 200 mg/tablet
POTASSIUM BROMIDE

For use with phenobarbitone as an
aid in the treatment of refractory
canine epilepsy

Contents: 200 Tablets

DIRECTIONS FOR USE: To be used concurrently with the existing dosage of phenobarbitone. If seizure control is attained, phenobarbitone dosage can be decreased as appropriate. To assist in adjustment of dose rate, monitor trough serum bromide concentrations at 30 and 120 days and at 6 monthly intervals or if adverse signs occur. Refer to pull out label for further information on monitoring and adverse signs. Administer once daily at meal time or as a divided dose twice daily with food.

DOSE RATE: One tablet per 5–10 kg (20–40 mg/kg) daily in single or divided dose.

FIRST AID: If poisoning occurs, contact a doctor or Poisons Information Centre. Telephone Australia 13 11 26.

STORAGE: Store below 30°C (Room Temperature)

DISPOSAL: Dispose of empty containers by wrapping with paper and putting in garbage.

INDICATIONS: Potassium bromide should be used in conjunction with phenobarbitone when seizures continue despite persistent trough phenobarbitone levels above 30 µg/mL for 1 or 2 months. Criteria for classifying idiopathic canine epileptics as refractory to phenobarbitone are: 1) seizure cause not identified; 2) phenobarbitone administered for at least 3 months with serum trough concentrations from 20 µg/mL to 40 µg/mL and a steady state trough concentration of 30 µg/mL without a subsequent change in dosage for at least 1 month before bromide initiation; and 3) seizure number and severity unchanged for at least 3 months despite therapy. Bromide therapy can also be commenced if there is evidence of hepatotoxicity which requires reduction in dosage of the antiepileptic. Concurrent bromide therapy can result in partial or complete control of epileptic seizures in a high percentage of cases.

DIRECTIONS FOR USE:

CONTRAINDICATION: Safety in pregnant animals has not been undertaken and therefore the use of bromide in pregnant animals is contraindicated.

SIDE EFFECTS: Bromide is generally well tolerated but side effects may occur and are generally related to excessive serum bromide concentrations. Most common adverse effects seen with combined therapy are increased lethargy, ataxia, polydipsia and polyuria. Occasionally, stupor, pancreatitis, hyperactivity and enhancement of pruritic dermatitis has been reported. These effects can be reversed by cessation of treatment for several days and commencement with a lower dosage and/or the intravenous infusion of 0.9% sodium chloride to enhance bromide excretion.




APVMA APPROVAL No.: 63154/200/0510

BATCH No.: _____ **EXPIRY DATE:** _____

MAVLAB
29-33 ROWLAND ST SLACKS CREEK QLD 4127
www.mavlab.com.au

This section covered and revealed on fold back

100% LABEL SIZE

-  Permanently adheres to container
-  Peel back section
-  Revealed section

NAME:	BROMAV 200 MG TABLETS FOR DOGS
APPLICANT:	MAVLAB PTY LTD
FILE NAME:	63154_44866_200T_LABEL_MPL_V2
DIMENSION:	ACTUAL LABEL SIZE = 220mm X 65mm
SCALE:	100% LABEL SIZE
DATE:	20/05/2010